Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy

Takuya Tsujino, Kazumasa Komura, Tomohisa Matsunaga, Yuki Yoshikawa, Tomoaki Takai, Taizo Uchimoto, Kenkichi Saito, Naoki Tanda, Rintaro Oide, Koichiro Minami, Hirofumi Uehara, Seong Ho Jeong, Kohei Taniguchi, Hajime Hirano, Hayahito Nomi, Naokazu Ibuki, Kiyoshi Takahara, Teruo Inamoto, Haruhito Azuma

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: The modified Glasgow Prognostic Score (mGPS) by measurement of serum C-reactive protein and albumin levels has been shown to provide prognostic value in various cancer types. The purpose of this study was to evaluate whether preoperative assessment of the mGPS predicts patient survival outcome in renal cell carcinoma (RCC). Materials and Methods: Clinicopathological and follow-up data in 219 RCC patients, all of whom underwent curative or non-curative nephrectomy, were collected. Overall survival (OS) and cancer-specific survival (CSS) after nephrectomy were evaluated, and univariate and multivariate analyses were conducted to assess the predictive value of the variables, including the mGPS. Results: During the median follow-up of 57 months, 53 patients (24.2%) were deceased within 22 months of the median OS. The 5-year OS rate from nephrectomy was 85.9 and 18.8% in non-metastatic (n = 195) and metastatic (n = 24) patients, respectively. Increasing mGPS was associated with shorter OS in non-metastatic patients (2-year OS rate of 98.2% in mGPS0, 73.3% in mGPS1, and 44.4% in mGPS2; hazard ratio [HR] 9.96, 95% confidence interval [CI] 4.88–20.13, p < 0.001), whereas no significant difference in OS according to the mGPS was seen in metastatic patients (HR 2.01, 95% CI 0.79–5.16, p = 0.137). On multivariate analysis, the mGPS remained as an independent predictor for OS (HR 5.24, 95% CI 1.39–19.77, p = 0.015) and CSS (HR 4.69, 95% CI 1.13–20.96, p = 0.034) in non-metastatic RCC patients. Conclusions: The mGPS appeared to be a reliable, preoperatively defined predictive marker with widely standardized protocol in non-metastatic RCC, and should therefore be considered in treatment decision making for RCC patients.

Original languageEnglish
Pages (from-to)2787-2793
Number of pages7
JournalAnnals of Surgical Oncology
Volume24
Issue number9
DOIs
Publication statusPublished - 01-09-2017
Externally publishedYes

Fingerprint

Nephrectomy
Renal Cell Carcinoma
Survival
Confidence Intervals
Multivariate Analysis
Survival Rate
Neoplasms
C-Reactive Protein
Blood Proteins
Albumins
Decision Making

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Tsujino, Takuya ; Komura, Kazumasa ; Matsunaga, Tomohisa ; Yoshikawa, Yuki ; Takai, Tomoaki ; Uchimoto, Taizo ; Saito, Kenkichi ; Tanda, Naoki ; Oide, Rintaro ; Minami, Koichiro ; Uehara, Hirofumi ; Jeong, Seong Ho ; Taniguchi, Kohei ; Hirano, Hajime ; Nomi, Hayahito ; Ibuki, Naokazu ; Takahara, Kiyoshi ; Inamoto, Teruo ; Azuma, Haruhito. / Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy. In: Annals of Surgical Oncology. 2017 ; Vol. 24, No. 9. pp. 2787-2793.
@article{7b360605fe384501a6751a59e8142dbe,
title = "Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy",
abstract = "Purpose: The modified Glasgow Prognostic Score (mGPS) by measurement of serum C-reactive protein and albumin levels has been shown to provide prognostic value in various cancer types. The purpose of this study was to evaluate whether preoperative assessment of the mGPS predicts patient survival outcome in renal cell carcinoma (RCC). Materials and Methods: Clinicopathological and follow-up data in 219 RCC patients, all of whom underwent curative or non-curative nephrectomy, were collected. Overall survival (OS) and cancer-specific survival (CSS) after nephrectomy were evaluated, and univariate and multivariate analyses were conducted to assess the predictive value of the variables, including the mGPS. Results: During the median follow-up of 57 months, 53 patients (24.2{\%}) were deceased within 22 months of the median OS. The 5-year OS rate from nephrectomy was 85.9 and 18.8{\%} in non-metastatic (n = 195) and metastatic (n = 24) patients, respectively. Increasing mGPS was associated with shorter OS in non-metastatic patients (2-year OS rate of 98.2{\%} in mGPS0, 73.3{\%} in mGPS1, and 44.4{\%} in mGPS2; hazard ratio [HR] 9.96, 95{\%} confidence interval [CI] 4.88–20.13, p < 0.001), whereas no significant difference in OS according to the mGPS was seen in metastatic patients (HR 2.01, 95{\%} CI 0.79–5.16, p = 0.137). On multivariate analysis, the mGPS remained as an independent predictor for OS (HR 5.24, 95{\%} CI 1.39–19.77, p = 0.015) and CSS (HR 4.69, 95{\%} CI 1.13–20.96, p = 0.034) in non-metastatic RCC patients. Conclusions: The mGPS appeared to be a reliable, preoperatively defined predictive marker with widely standardized protocol in non-metastatic RCC, and should therefore be considered in treatment decision making for RCC patients.",
author = "Takuya Tsujino and Kazumasa Komura and Tomohisa Matsunaga and Yuki Yoshikawa and Tomoaki Takai and Taizo Uchimoto and Kenkichi Saito and Naoki Tanda and Rintaro Oide and Koichiro Minami and Hirofumi Uehara and Jeong, {Seong Ho} and Kohei Taniguchi and Hajime Hirano and Hayahito Nomi and Naokazu Ibuki and Kiyoshi Takahara and Teruo Inamoto and Haruhito Azuma",
year = "2017",
month = "9",
day = "1",
doi = "10.1245/s10434-017-5948-6",
language = "English",
volume = "24",
pages = "2787--2793",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "9",

}

Tsujino, T, Komura, K, Matsunaga, T, Yoshikawa, Y, Takai, T, Uchimoto, T, Saito, K, Tanda, N, Oide, R, Minami, K, Uehara, H, Jeong, SH, Taniguchi, K, Hirano, H, Nomi, H, Ibuki, N, Takahara, K, Inamoto, T & Azuma, H 2017, 'Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy', Annals of Surgical Oncology, vol. 24, no. 9, pp. 2787-2793. https://doi.org/10.1245/s10434-017-5948-6

Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy. / Tsujino, Takuya; Komura, Kazumasa; Matsunaga, Tomohisa; Yoshikawa, Yuki; Takai, Tomoaki; Uchimoto, Taizo; Saito, Kenkichi; Tanda, Naoki; Oide, Rintaro; Minami, Koichiro; Uehara, Hirofumi; Jeong, Seong Ho; Taniguchi, Kohei; Hirano, Hajime; Nomi, Hayahito; Ibuki, Naokazu; Takahara, Kiyoshi; Inamoto, Teruo; Azuma, Haruhito.

In: Annals of Surgical Oncology, Vol. 24, No. 9, 01.09.2017, p. 2787-2793.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy

AU - Tsujino, Takuya

AU - Komura, Kazumasa

AU - Matsunaga, Tomohisa

AU - Yoshikawa, Yuki

AU - Takai, Tomoaki

AU - Uchimoto, Taizo

AU - Saito, Kenkichi

AU - Tanda, Naoki

AU - Oide, Rintaro

AU - Minami, Koichiro

AU - Uehara, Hirofumi

AU - Jeong, Seong Ho

AU - Taniguchi, Kohei

AU - Hirano, Hajime

AU - Nomi, Hayahito

AU - Ibuki, Naokazu

AU - Takahara, Kiyoshi

AU - Inamoto, Teruo

AU - Azuma, Haruhito

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Purpose: The modified Glasgow Prognostic Score (mGPS) by measurement of serum C-reactive protein and albumin levels has been shown to provide prognostic value in various cancer types. The purpose of this study was to evaluate whether preoperative assessment of the mGPS predicts patient survival outcome in renal cell carcinoma (RCC). Materials and Methods: Clinicopathological and follow-up data in 219 RCC patients, all of whom underwent curative or non-curative nephrectomy, were collected. Overall survival (OS) and cancer-specific survival (CSS) after nephrectomy were evaluated, and univariate and multivariate analyses were conducted to assess the predictive value of the variables, including the mGPS. Results: During the median follow-up of 57 months, 53 patients (24.2%) were deceased within 22 months of the median OS. The 5-year OS rate from nephrectomy was 85.9 and 18.8% in non-metastatic (n = 195) and metastatic (n = 24) patients, respectively. Increasing mGPS was associated with shorter OS in non-metastatic patients (2-year OS rate of 98.2% in mGPS0, 73.3% in mGPS1, and 44.4% in mGPS2; hazard ratio [HR] 9.96, 95% confidence interval [CI] 4.88–20.13, p < 0.001), whereas no significant difference in OS according to the mGPS was seen in metastatic patients (HR 2.01, 95% CI 0.79–5.16, p = 0.137). On multivariate analysis, the mGPS remained as an independent predictor for OS (HR 5.24, 95% CI 1.39–19.77, p = 0.015) and CSS (HR 4.69, 95% CI 1.13–20.96, p = 0.034) in non-metastatic RCC patients. Conclusions: The mGPS appeared to be a reliable, preoperatively defined predictive marker with widely standardized protocol in non-metastatic RCC, and should therefore be considered in treatment decision making for RCC patients.

AB - Purpose: The modified Glasgow Prognostic Score (mGPS) by measurement of serum C-reactive protein and albumin levels has been shown to provide prognostic value in various cancer types. The purpose of this study was to evaluate whether preoperative assessment of the mGPS predicts patient survival outcome in renal cell carcinoma (RCC). Materials and Methods: Clinicopathological and follow-up data in 219 RCC patients, all of whom underwent curative or non-curative nephrectomy, were collected. Overall survival (OS) and cancer-specific survival (CSS) after nephrectomy were evaluated, and univariate and multivariate analyses were conducted to assess the predictive value of the variables, including the mGPS. Results: During the median follow-up of 57 months, 53 patients (24.2%) were deceased within 22 months of the median OS. The 5-year OS rate from nephrectomy was 85.9 and 18.8% in non-metastatic (n = 195) and metastatic (n = 24) patients, respectively. Increasing mGPS was associated with shorter OS in non-metastatic patients (2-year OS rate of 98.2% in mGPS0, 73.3% in mGPS1, and 44.4% in mGPS2; hazard ratio [HR] 9.96, 95% confidence interval [CI] 4.88–20.13, p < 0.001), whereas no significant difference in OS according to the mGPS was seen in metastatic patients (HR 2.01, 95% CI 0.79–5.16, p = 0.137). On multivariate analysis, the mGPS remained as an independent predictor for OS (HR 5.24, 95% CI 1.39–19.77, p = 0.015) and CSS (HR 4.69, 95% CI 1.13–20.96, p = 0.034) in non-metastatic RCC patients. Conclusions: The mGPS appeared to be a reliable, preoperatively defined predictive marker with widely standardized protocol in non-metastatic RCC, and should therefore be considered in treatment decision making for RCC patients.

UR - http://www.scopus.com/inward/record.url?scp=85021133755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021133755&partnerID=8YFLogxK

U2 - 10.1245/s10434-017-5948-6

DO - 10.1245/s10434-017-5948-6

M3 - Article

C2 - 28643013

AN - SCOPUS:85021133755

VL - 24

SP - 2787

EP - 2793

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 9

ER -